Background: The carboxy-terminus of the merozoite surface protein-i (MSP1) of Plasmodium falciparum has
INTRODUCTION
Malaria is a problem of serious and increasing proportions. Effective antimalarial vaccines offer hope in reducing morbidity and mortality from malaria in such a deteriorating situation. A number of parasite molecules from various stages of the parasite's life cycle have been suggested as vaccine candidates. One of the most studied antigens from the asexual blood stages of the life cycle is the 195-kD merozoite surface protein-I (MSP1) (1) . MSP1 is processed by proteolytic cleavage into a series of distinct fragments (2, 3) . These fragments remain associated through noncovalent linkages and are attached to the merozoite surface by the carboxy-terminal 42-kD fragment (MSP142) . Around the time of red blood cell (RBC) invasion by merozoites, MSP142 is further processed into a 33-kD soluble polypeptide and a membrane-bound 19 -kD carboxyterminal fragment (MSP 1I9). MSP1I9, which consists of two cysteine-rich EGF-like domains and a GPI anchor, continues to be present on ring forms in newly invaded RBCs (4, 5) . Several lines of evidence suggest that the carboxy-terminal fragments of MSP1 are targets of protective immunity: immunization/challenge studies with recombinant MSPII9 in a murine model (6, 7) ; and in vitro inhibition of erythrocyte invasion with anti-MSPlI9 monoclonal (4) and anti-MSP142 polyclonal antibodies (8) .
The mechanism of protective immunity in humans is presently unclear: antibodies, cytokines, and antibody-dependent cellular inhibition have all been implicated. Therefore, until the mechanism(s) of in vivo efficacy has been elucidated, in vitro tests are of limited value. Aotus We planned to construct a shuttle plasmid that would secrete from Saccharomyces cerevisiae a fusion protein consisting of the P30 and P2 universal helper T cell epitopes of tetanus toxoid (9) fused to MSP 119. To express P30, a cassette was made using synthetic oligonucleotides (sense oligonudeotides 5'-CTGGTACCTITTGGATAAAAGAG ACGCTGAAGCTTCTlTGGATAAAAGATTCAACAA CTTCACTGTC-3' and 5'-TCTlTCTGGTTGAGAGTTA AGGTCTCCGCCTCCCACCTCGAGAAC-3' and antisense oligonudeotides 5'-GTTCTCGAGGTGGGAG GCGGAGACCTITAACTCTCAACCAGAAAGAGACA GTGAAGTTGTTGAA-3' and 5'-TC'T'ITrATCCAAAG AAGCTTCAGCGTCTC lTITATCCAAAGGTACCAG-3') to encode tetanus toxoid amino acids 947-967, FNNFIJVSFWLRVKVSASHLE (9) . The P2 epitope was also constructed using oligonudeotides (sense 5'-CCGCTCGAGCAATACATTAAGGCTAACTCTAA GTTCATTGGTATTACTGAAGTCGACGAATICCCGG-3' and antisense 5'-CCGGAATTCGTCGACTTCAGT AATACCAATGAACTTAGAGTTAGCCTTAATGTATT GCTCGAGCGG-3') encoding tetanus toxoid amino acids 830-843, QYIKANSKFIG1TE (9 The other fusion protein, bMSP142, designed to be expressed intracellularly in E. coli, was constructed with glutathione-S-transferase (GST) from S. mansoni fused to the amino-terminus of MSP142. Both yMSP1,9 and bMSP142 proteins were recognized in ELISA and on Western blot by Fig. 1 E and F) . The course of parasitemia in these animals was similar to that previously observed in A. nancymai monkeys infected with the FVO strain of P. falciparum (13) . In the group of four monkeys immunized with bMSPI42, one monkey died after the first immunization. Upon challenge infection, A. nancymai (202) and A. vociferans (T212) were unprotected, and one A. nancymai (E851) controlled the initial peaks of parasitemia ( Fig. 1 C and D) . Monkey E851 had no detectable parasites from Day 18 through Day 22, but eventually developed a 1% parasitemia on Day 28 and required chemotherapy because of severe anemia.
The two A. vociferans immunized with yMSP II9
were not protected (Fig. iB) It remains to be determined whether antibody-independent, T cell-mediated mechanisms also contributed to immunity. The notion of cellmediated immunity was suggested in the initial murine immunization studies using purified Plasmodium yoelii MSP1 (18) (19) (20) . Transfer of sera from immune mice did not transfer protection; rather, protection was correlated with delayedtype hypersensitivity to malaria parasites (20) . However, antibody from mice immunized with a MSP-1 construct similar to the one used in the present study did transfer protection in a rodent malaria, P. yoelii (C. A. Long, personal communication). The MSP-1 vaccine in this rodent model was previously shown to give a high level of protection, indicating that the protection is at least in part antibody-mediated (6) .
In previous studies, the FVO strain of P. falciparum caused a universally virulent infection in A. nancymai (Ref. 13 and S. Kumar, unpublished observations). That two of two A. nancymai were highly protected (maximum parasitemia of 0.1 %) in the present study suggests that immunization with MSP 19 induces an effective immune response. The virulent course we observed in A. vociferans after immunization with yMSP 1 9 may reflect the fact that this species of Aotus, for unknown reasons, is more susceptible to infection by P. falciparum. For example, several strains of P. falciparum (FUP, Malay IV, Indochina, and FVO) follow a virulent course in A. vociferans, but only FVO is consistently virulent in A. nancymai (Ref. 13 
